<< Revenir à la page d'accueil
13th november 2012
Maison de la Chimie, Paris
The Dependence Receptor paradigm: A door to targeted therapy
Patrick MEHLEN
Inserm CNRS - Université de Lyon - Centre Léon Bérard, Lyon
⤢
The Dependence Receptor paradigm: A door to targeted therapy
Basic Science to Clinical Trial
Against the dogma: The Dependence Receptor (DR) notion
The Dependence Receptor family
DRs as constraints for tumor progression
DRs as regulators of tumor progression...
Inhibition of DCC-induced apoptosis in mouse is associated with cancer progression...
Gain of DR's ligand as a selective advantage for tumor progression...
Inhibition of the netrin-1 autocrine loop triggers cancer cell death
Interference with netrin-1/receptors interaction inhibits mammary metastasis
Interference with netrin-1 prevents Lung cancer progression
From concept to clinic: Netris Pharma
The Dependence Receptor family
Netris Pharma IP and Pipeline
Conclusion and Perspectives
Thank You
|«
«
▶||
»
»|
0:00:00